Luhan Pharmachem Co., Ltd.
On April 17, 2018, the Food and Drug Administration approved fostamatinibdisodium hexahydrate tablets (TAVALISSE, Ri 04-25
FDAapproves nivolumab plus ipilimumab combination for intermediate or poor-riskadvanced renal cell carcinoma On Apr 04-24
FDArestricts sale and distribution of Essure to protect women and to require thatpatients receive risk informationT 04-24
FDAexpands approval of Blincyto for treatment of a type of leukemia in patientswho have a certain risk factor fo 03-30
FDAexpands approval of Blincyto for treatment of a type of leukemia in patientswho have a certain risk factor fo 03-30
FDAexpands approval of Blincyto for treatment of a type of leukemia in patientswho have a certain risk factor fo 03-30
FDAapproves nilotinib for pediatric patients with newly diagnosed orresistant intolerant Ph+ CML in chronic phase On 03-27
FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy03-21
Ongoing clinical study shows an increased risk of death and fractures with the combination03-16
Amglidia is a new formulation ofglibenclamide, specifically developed for use in newborns, toddlers andchildrenThe E 02-24
FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing02-22
The U S Food and Drug Administration todayapproved Lutathera (lutetium Lu 177 dotatate) for the treatment of a t 02-01
Tel: +86 0871 6511 0906 (GMT+8 AM9:00-AM:12:00 PM1:30-PM6:00)
cell phone:188 1221 6310
Fax:0871-63602606
Email: info@luhancn.com
Address:Room 3301,33rd Floor Building B, Vogue Garden Plaza, No.1004 Beijing Road, Kunming, Yunnan Province, P. R. China 650000